Scientists have long sought to characterize the pathophysiologic basis of schizophrenia and
develop biomarkers that could identify the illness. Extensive postmortem and in vivo …

Glutamate is the primary excitatory neurotransmitter in mammalian brain. Disturbances in
glutamate-mediated neurotransmission have been increasingly documented in a range of …

Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both
have been proposed to contribute significantly to the pathophysiology of schizophrenia. In …

Economics and mental health are intertwined. Apart from the accumulating evidence of the
huge economic impacts of mental ill‐health, and the growing recognition of the effects that …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

The discovery of the antidepressant effects of ketamine has opened a breakthrough
opportunity to develop a truly novel class of safe, effective, and rapid-acting antidepressants …

The hippocampus in schizophrenia is characterized by both hypermetabolism and reduced
size. It remains unknown whether these abnormalities are mechanistically linked. Here we …

Neurons in the primate dorsolateral prefrontal cortex (dlPFC) generate persistent firing in the
absence of sensory stimulation, the foundation of mental representation. Persistent firing …

The ability of ketamine administration to activate prefrontal glutamate neurotransmission is
thought to be a key mechanism contributing to its transient psychotomimetic effects and its …

The N-methyl-d-aspartate receptor (NMDAR) hypofunction hypothesis has been proposed to
help understand the etiology and pathophysiology of schizophrenia. This hypothesis was …